Loading...
Loading chart...



The current price of PTPI is 0 USD — it has increased 0 % in the last trading day.
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Wall Street analysts forecast PTPI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTPI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Petros Pharmaceuticals Inc revenue for the last quarter amounts to 725.40K USD, decreased % YoY.
Petros Pharmaceuticals Inc. EPS for the last quarter amounts to -1.07 USD, decreased % YoY.
Petros Pharmaceuticals Inc (PTPI) has 18 emplpoyees as of February 09 2026.
Today PTPI has the market capitalization of 3.12M USD.